Category: 3. Business

Steel solutions for Structural Fire Protection, Thermal, and Acoustic.

Insulation is no longer a passive component in vessel design—it directly influences safety, efficiency, and onboard comfort. Isover, available through Imtra, is setting a new standard with high-performance systems engineered for the realities of modern marine operations.

Isover’s mineral wool insulation systems are engineered to perform in harsh marine environments, delivering certified fire protection in accordance with the IMO FTP Code, including A-class division requirements, alongside thermal efficiency and acoustic control across a broad range of vessel and offshore applications.

Aluminum solutions for Structural Fire Protection, Thermal, and Acoustic.

At the core of Isover’s marine insulation is a proprietary fiberization process that produces long, uniform fibers while eliminating the slag commonly found in conventional mineral wool. By removing these non-fibrous elements—a source of thermal bridging—and extending fiber length, the material achieves required thermal, acoustic, and fire performance at lower densities and reduced thicknesses, while improving flexibility. This allows the insulation to conform to complex ship structures without breaking, reducing installation labor and material waste.

From passenger ferries and luxury yachts to offshore platforms and naval vessels, Isover insulation is engineered to meet IMO standards. It also carries U.S. Coast Guard recognition under the EU–U.S. Mutual Recognition Agreement (MRA), with Module B type approval supporting U.S. acceptance of MED-certified equipment. Together, these certifications ensure materials resist ignition, limit flame spread and minimize smoke and toxic emissions—critical to protecting both passengers and crew.

One of the key advantages of Isover insulation is its lightweight design. Compared to traditional stone wool, U SeaProtect® can be up to 40–45% lighter and significantly thinner, without sacrificing performance.

This reduction in weight directly improves vessel efficiency. Lighter ships consume less fuel, reducing both operating costs and carbon emissions—an increasingly critical factor in modern vessel design.

Multiple facings and self sealing tape options.

Efficiency doesn’t stop at performance. Isover insulation is designed with installation in mind. Its flexibility and roll format reduce the need for cutting and trimming, lowering material waste and installation time. In many cases, waste can drop from around 15% to 5%, delivering measurable cost savings and improved schedule certainty.

While safety and efficiency are paramount, Isover also enhances the onboard environment. Its insulation systems reduce noise levels and maintain stable interior temperatures, creating quieter, more controlled living and working conditions.

This is particularly important in passenger cabins, crew quarters, and recreational areas, where acoustic comfort and climate control directly impact wellbeing. By minimizing noise and improving thermal stability, Isover contributes to a more consistent onboard environment.

Quick cover method for stiffener insulation.

The Bottom Line

Isover insulation is more than a protective layer—it is an integrated system that supports safety, efficiency, and onboard performance across a wide range of vessel types. Distributed in the U.S. by Imtra, it provides a practical solution for shipbuilders and operators seeking to meet current standards while improving overall vessel performance.

For shipbuilders, engineers, and operators, the value is not just in meeting requirements, but in how those requirements are achieved. Isover delivers insulation that performs in application—where weight, installation, and long-term durability ultimately matter most.

Specialty

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

BEIJING, March 29 (Xinhua) — At an exhibition held during the ongoing 2026 Zhongguancun Forum (ZGC Forum) in Beijing, a range of brain-computer interface (BCI) products — from specialized chips to rehabilitation systems — drew large crowds.

“Brain-computer interface technology is advancing rapidly, and its applications are expanding,” said Zhao Jizong, a neurosurgery expert and an academician with the Chinese Academy of Sciences, while sharing the latest BCI progress on Friday at the Brain-Computer Interface Innovation Development Forum, a session of the 2026 ZGC Forum Annual Conference.

Among the exhibition products, two domestically developed intelligent systems, known as “Beinao-1” and “Beinao-2,” attracted particular attention. Zhao noted that “Beinao-1,” a semi-invasive BCI system, has been implanted in seven patients. All have recovered well and regained movement and speech functions. “Beinao-2” will enter clinical verification this year.

A BCI creates a direct communication pathway between the brain and an external device. By recording and interpreting brain signals, BCI allows the brain to “talk” directly to machines, enabling patients to control assistive devices.

As a frontier technology in human-computer interaction, BCI has been driving a new wave of technological and industrial transformation. China has introduced a series of policies to strengthen BCI research and industrial deployment. The BCI sector has been designated as a future industry in this year’s government work report.

At the forum, experts from research institutions, hospitals, universities and companies shared experiences and held discussions on BCI technology and its industrial applications.

Gu Xiaosong, an academician with the Chinese Academy of Engineering, noted that since 2025, China’s BCI development has accelerated significantly, with various technologies entering the application verification phase and yielding impressive results.

In recent years, medical institutions in Beijing, Tianjin, Guangzhou, Wuhan, Nanjing and other cities have set up BCI clinics or clinical research wards. A range of BCI products developed in China has been applied in areas such as disease diagnosis, motor rehabilitation and neuromodulation treatment for conditions like Parkinson’s disease and epilepsy.

This month, China’s National Medical Products Administration approved the world’s first invasive BCI medical device for market. The equipment is intended for patients who suffer from quadriplegia caused by cervical spinal cord injuries and are unable to perform grasping movements with their fingers.

Zhao noted that China faces serious challenges from neurological diseases such as stroke, amyotrophic lateral sclerosis and spinal cord injury, with a large patient population, including more than 3.7 million people living with spinal cord injuries. BCI has opened a new path for rehabilitation treatment, and clinical demand is high.

Local governments across China are building service platforms. Lin Hang, deputy head of Beijing’s Haidian District, said at the forum that the district is already home to 27 core BCI companies. By 2030, it aims to attract about 100 innovative small and medium-sized enterprises and promote large-scale commercial application of BCI products in medical care, rehabilitation, industry, education and other fields, creating a hub for “AI plus BCI” innovation.

Despite the rapid growth of the BCI industry, experts have noted that challenges remain in areas such as technical reliability, safety and ethics, requiring continued steady exploration.

“We need breakthroughs not only in technological innovation but also in building a complete ecosystem covering industrial development, talent cultivation and standard setting,” Gu said.  ■

• LVMH Moët Hennessy – Louis Vuitton Société Européenne (ENXTPA:MC) is contending with strong luxury demand in India alongside a shortage of prime retail space.
• High quality luxury malls are in short supply, and new projects are planned but not yet available for brands to occupy.
• The situation is creating both near term constraints and longer term opportunities for LVMH and other global luxury groups targeting India.

For LVMH, which spans fashion, leather goods, spirits, beauty and watches, India is an important market where many consumers are entering higher income brackets and showing interest in luxury brands. At the same time, there are only a limited number of locations that match LVMH’s typical store standards, so the group’s physical rollout is tied closely to how fast premium malls and retail streets become available.

For you as an investor, the India story around ENXTPA:MC is less about immediate store counts and more about how the company positions itself while supply of suitable space catches up with demand. Choices on partnerships, store formats and timing of openings in India could influence how much of this demand LVMH captures compared with rival luxury houses across Asia.

Stay updated on the most important news stories for LVMH Moët Hennessy – Louis Vuitton Société Européenne by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on LVMH Moët Hennessy – Louis Vuitton Société Européenne.

3 things going right for LVMH Moët Hennessy – Louis Vuitton Société Européenne that this headline doesn’t cover.

Quick Assessment

• ✅ Price vs Analyst Target: At €455.75, the share price sits about 27% below the €622.58 analyst target.
• ❌ Simply Wall St Valuation: The shares are assessed as trading roughly 44% above estimated fair value.
• ❌ Recent Momentum: The 30 day return of about 17.6% decline signals weak short term momentum.

There is only one way to know the right time to buy, sell or hold LVMH Moët Hennessy Louis Vuitton Société Européenne. Head to Simply Wall St’s
company report for the latest analysis of LVMH Moët Hennessy Louis Vuitton Société Européenne’s Fair Value.

Key Considerations

• 📊 The India luxury space shortage can cap near term store roll out, while still supporting brand desirability as demand runs ahead of physical presence.
• 📊 Watch how quickly new luxury malls open, LVMH’s store count in India, and whether the current P/E of 20.8x stays below the luxury industry average of 26.5x.
• ⚠️ With one flagged risk around an unstable dividend track record, income focused investors may want to weigh this against the growth driven India opportunity.

Dig Deeper

For the full picture including more risks and rewards, check out the
complete LVMH Moët Hennessy Louis Vuitton Société Européenne analysis. Alternatively, you can check out the
community page for LVMH Moët Hennessy Louis Vuitton Société Européenne to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Alibaba Group Holding Limited and other Chinese tech firms are accelerating a shift toward domestic AI chips as U.S. restrictions on Nvidia Corp. reshape the competitive landscape and boost Huawei’s position.

Alibaba and ByteDance are preparing to order Huawei’s latest AI chips after customer testing delivered strong results, marking a shift from earlier hesitation around Huawei’s Ascend 910C, Reuters reported on Friday, citing sources familiar with the matter. The improved reception signals growing acceptance of domestic alternatives among China’s largest tech players.

Don’t Miss:

Huawei is gaining traction with its new 950PR chip due to improved compatibility with Nvidia’s CUDA ecosystem and faster performance. The company began sending samples in January and plans to start mass production soon, targeting around 750,000 units in 2026, with broader shipments expected in the second half of the year.

U.S. restrictions on advanced Nvidia chips are creating an opening for Huawei and other local players, while China accelerates efforts to build its own semiconductor capacity.

Companies such as Semiconductor Manufacturing International Corporation and Hua Hong Semiconductor Limited are expanding advanced chip production, aiming to significantly increase output despite equipment constraints.

At the same time, JPMorgan analyst Harlan Sur said Nvidia still holds significant upside if export approvals improve, estimating that every 100,000 H200 GPUs shipped to China could generate about $3 billion in revenue. He noted that case-by-case approvals could reopen the market, with strong Chinese demand ready to convert into revenue if restrictions ease.

Trending: This Startup Thinks It Can Reinvent the Wheel — Literally

Nvidia is trading 4.2% below its 20-day simple moving average (SMA) and 6.7% below its 100-day SMA, keeping the intermediate trend under pressure even as the stock tries to firm up.

Shares are up 53.67% over the past 12 months, and the stock is closer to its 52-week lows than its highs, trading in the $86.62 to $212.19 range.

The RSI is at 39.02, which sits in neutral territory but closer to the “washed-out” side of the range than to overbought conditions. Meanwhile, MACD is at -2.7707 and remains below its signal line at -1.9507, reinforcing bearish momentum.

The combination of an RSI below 50 and a bearish MACD suggests mixed momentum, with downside pressure still outweighing the early bounce.

• Key Resistance: $194.00

• Key Support: $170.50

Looking further out, the next major catalyst for the stock arrives with the May 27, 2026 (estimated) earnings report.

• EPS Estimate: $1.74 (Up from 96 cents YoY)

• Revenue Estimate: $78.71 Billion (Up from $44.06 Billion YoY)

• Valuation: P/E of 34.9x (Indicates premium valuation relative to peers)

See Also: This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $281.04. Recent analyst moves include:

• Rosenblatt: Buy (Maintains Target to $325.00) (Mar. 23)

• Cantor Fitzgerald: Overweight (Maintains Target to $300.00) (Mar. 23)

• Raymond James: Strong Buy (Raises Target to $323.00) (Mar. 19)

• Amplify CWP Growth & Income ETF (NYSE:QDVO): 9.73% Weight

• REX AI Equity Premium Income ETF (NASDAQ:AIPI): 9.97% Weight

• Xtrackers Net Zero Pathway Paris Aligned U.S. Equity ETF (NYSE:USNZ): 9.58% Weight

Significance: Because NVDA carries such a heavy weight in these funds, any significant inflows or outflows will likely trigger automatic buying or selling of the stock.

Read Next: Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.

Photo via Shutterstock

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga:

This article Huawei Targets Nvidia’s Turf With New AI Chip originally appeared on Benzinga.com

Specialty

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

NEW ORLEANS, LA—For patients with uncontrolled hypertension already on two or more medications, monthly injections of tonlamarsen (Kardigan) more effectively lowered plasma angiotensinogen (AGT) levels than a single dose of the novel drug, according to results from the phase II KARDINAL trial. But repeat dosing did not lead to greater reductions in blood pressure over 20 weeks.

Luke J. Laffin, MD (Cleveland Clinic Foundation, OH), presented the results today at the American College of Cardiology (ACC) 2026 Scientific Session.

 Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero to one medication. However, more data are needed in patients taking multiple medications, including ACE inhibitors and angiotensin receptor blockers.”

AGT is a precursor for all peptides generated in the renin-angiotensin-aldosterone system (RAAS).

Daniel W. Jones, MD (University of Mississippi, Jacksonville), a past president of the American Heart Association and writing committee chair for the 2025 US hypertension guidelines, cautioned that KARDINAL is a phase II trial that represents the early stages of investigation on tonlamarsen.

“It’s too early to really understand how and if this drug fits into clinical management of hypertension,” he told TCTMD in an email. “Similar to a few other investigational drugs, it might offer the potential for periodic drug injection as opposed to daily oral use to improve adherence. Patients are more likely to adhere to treatment plans when they are easier to follow; therefore, periodic injections may be preferred versus remembering to take a daily pill.”

Several additional drugs, as reported by TCTMD, are being explored as solutions to the vexing problem of treatment-resistant hypertension.

Zilebesiran (Alnylam Pharmaceuticals), a small interfering RNA agent that, like tonlamarsen, targets AGT production, has previously shown promise in the KARDIA-2 trial. Taking a different approach is lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor studied in the Advance-HTN trial. Another aldosterone synthase inhibitor, baxdrostat (CinCor Pharma) failed to show a benefit over placebo in the phase II HALO trial but did do so previously in BrigHTN. Additionally, there’s aprocitentan (Tryvio; Idorsia Pharmaceuticals), an endothelin receptor antagonist that was approved by the US Food and Drug Administration in 2024 for uncontrolled hypertension.

The KARDINAL Trial

KARDINAL enrolled adults with an office systolic BP greater than 135 mm Hg despite already receiving two to five antihypertensive drugs. More than 80% were on an ACE inhibitor or ARB. All had an eGFR greater than 30 mL/min/1.73 m².

The mean age among randomized patients was 61 years, 59% were women, 33% had diabetes, 11% had an eGFR > 60 mL/min/1.73 m², and 49% were Black.

The study involved three phases that started with a 4-week placebo lead-in period (n = 279), followed by a 4-week active run-in period during which patients (n = 206) received a single subcutaneous 90-mg injection of tonlamarsen. Following these 8 weeks, participants (n = 198) were randomized to receive either four additional tonlamarsen doses or matching placebo for 16 weeks.

KARDINAL had two primary endpoints: change from baseline to week 20 in plasma AGT and in clinic-measured systolic BP levels.

The mean in-office BP was 147/90 mm Hg before the placebo lead-in and 147/89 mm Hg after. After the active run-in period, mean BP was 140/87 mm Hg. Twenty weeks after the first tonlamarsen dose, the least-squares (LS) mean change in office systolic BP was nearly identical between the single-dose group (-6.7 mm Hg; 95% CI -9.8 to -3.5) and the monthly-dose group (-6.7 mm Hg; 95% CI -9.8 to -3.6; P = 0.97).

There was an advantage for monthly dosing when it came to plasma AGT. By week 20, patients randomized to a single tonlamarsen dose had an LS mean percent change of -23.0% (95% CI -27.8 to -18.2%), as compared to -67.2% (95% CI -71.9 to -62.4%) with monthly dosing (P < 0.0001).

Serious adverse events occurred in 2.1% of the single-dose group and 5.0% of the monthly-dose group, with the latter also experiencing more injection-site reactions. One patient receiving monthly tonlamarsen died, though the site investigator deemed the death unrelated to the study drug.

A New Target?

“Nucleic acid-based therapeutics decreasing hepatic AGT synthesis represent a new approach to RAAS modulation with drugs that are durable and not dependent on daily adherence,” the investigators note in their paper. “Hepatic AGT suppression targets the dominant source of circulating AGT and may provide more sustained reduction across dosing intervals in the downstream products of AGT, such as angiotensin II.”

KARDINAL, unfortunately, does not provide a clear answer on whether targeting AGT can ultimately lead to lower blood pressure for patients already on several antihypertensive medications, they say. The continued suppression of AGT 20 weeks after the single tonlamarsen dose was unanticipated given that the drug has an elimination half life between 2 and 4 weeks.

Morris Brown, MD (Queen Mary University of London, England), the senior investigator for the BrigHTN trial of baxdrostat, told TCTMD that he’s not convinced that it makes sense to target AGT in patients already on an ACE inhibitor and/or ARB, given that those drugs already target the RAAS. What AGT suppression might offer beyond these conventional therapies isn’t so much BP-lowering, he said, but rather the “possible convenience of only having to deliver the drug,” in this case monthly.

Additionally, “since angiotensinogen levels are not the rate-limiting step in determining the level of angiotensin II (the active molecule) in most patients, it is likely that near 100% reductions are required to achieve an effect on BP. We have known this for other components of the renin-angiotensin system—effective doses of an ACE inhibitor reduce enzyme activity by near 100%,” Brown explained.

Laffin suggested several reasons for the lack of difference in BP in KARDINAL.

“The first is that a single dose of tonlamarsen may result in sustained office blood pressure reduction, even as angiotensinogen suppression remains. The second is that residual AGT suppression may have attenuated the between-treatment-group differences in office blood pressure, [thus] requiring larger studies in larger sample size. And finally, he added, “it can’t be excluded, although I think this is less likely, that improved adherence to background medications or additional regression to the mean in blood pressure occurred following the placebo lead-in.”

A limitation of the trial, said Laffin, is its lack of a placebo-only comparator arm.

John D. Bucheit, PharmD (Virginia Commonwealth University, Richmond), a member of the ACC Prevention Council who took part in the press conference, agreed, but said the trial nevertheless looks at a key clinical need.

“Hypertension is a major problem that we all see, and our control rates in the US are less than what we’d like. So having novel treatment options is really important,” said Bucheit. The take-home here is that “this medication definitely reduces angiotensinogen, and so this is a potential target in therapy. What I think is important going forward is we are going to need those placebo-controlled arms.”

To TCTMD, Jones pointed out that KARDINAL’s design featuring a 4-week active run-in period is not common and “might make it more difficult to evaluate BP-lowering effectiveness.” The area most ripe for research, he added, is understanding what factors might be causing the resistance to treatment.

A large shipment of KitKat candy bars was stolen while in transit to distributors, a major candy crime right before the Easter holiday that could cause shortages for customers.

The truck carrying 413,793 units of a “new chocolate range”, about 12 tons of chocolate bars, was pilfered while driving through Europe on 26 March, Agence France-Presse reported.

A spokesperson for Nestlé, KitKat’s parent company, confirmed the theft to the Guardian, adding that the company is investigating the theft with local authorities and supply chain partners.

The stolen truck left a factory in central Italy and was en-route to Poland when the robbery occurred, according to a statement from Nestlé. The vehicle and the carried-off chocolate have not been located. No one was hurt during the heist, a Nestlé spokesperson told the Athletic.

“We’ve always encouraged people to have a break with KitKat,” said Nestlé in a statement, riffing off the KitKat slogan. “But it seems thieves have taken the message too literally and made a break with more than 12 tons of our chocolate.”

The statement continued: “Whilst we appreciate the criminals’ exceptional taste, the fact remains that cargo theft is an escalating issue for businesses of all sizes. With more sophisticated schemes being deployed on a regular basis, we have chosen to go public with our own experience in the hope that it raises awareness of an increasingly common criminal trend.”

The stolen bars were from KiKat’s new Formula One line, a result of KitKat’s becoming the official F1 chocolate bar last year, the Athletic reported. The candy bars were molded after race cars, still featuring KitKat’s iconic chocolate-covered wafers.

Due to the theft, the stolen KitKat bars could make their way into unofficial markets, Nestlé warned.

Company officials said that if that does occur, law enforcement can trace stolen products through batch codes assigned to individual bars.